## MOH: Molina Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.5% below STRENGTH zone (4.0-10.0%); PEG 2.53 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($152.81)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bearish (Bullish: 0, Bearish: 7)

**1. Bronstein, Gewirtz & Grossman, LLC Encourages Molina Healthcare, Inc. (MOH) Stockholders to Inquire about Securities Investigation**
- Source: KWKT - FOX 44 | 20251223T160817 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (NYSE:MOH) securities. The investigation focuses on whether Molina and its officers engaged in corporate wrongdoing. Investors who bought Molina securities prior to February 5, 2025, and still hold them, are encouraged to contact the firm for more information regarding this securities investigation.

**2. Bronstein, Gewirtz & Grossman, LLC Encourages Molina Healthcare, Inc. (MOH) Stockholders to Inquire about Securities Investigation**
- Source: WIVB News 4 | 20251223T160811 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Molina Healthcare, Inc. (MOH) regarding corporate wrongdoing. The firm encourages stockholders who purchased Molina securities before February 5, 2025, and still hold them, to contact them for more information and to assist in the investigation. The representation of investors in class actions is on a contingency fee basis.

**3. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Molina Healthcare, Inc. (MOH) and Encourages Investors to Learn More About the Investigation**
- Source: KSNT 27 News | 20251222T040803 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) for alleged corporate wrongdoing. The firm is encouraging investors who purchased Molina securities before February 5, 2025, and still hold them, to assist with the investigation. This investigation focuses on potential claims against Molina and its officers/directors.

**4. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Molina Healthcare, Inc. (MOH) and Encourages Investors to Learn More About the Investigation**
- Source: FOX40 News | 20251221T160907 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) concerning potential corporate wrongdoing by the company and its officers/directors. Investors who purchased Molina securities prior to February 5, 2025, and still hold them, are urged to contact the firm for more information and to assist in the investigation. The firm operates on a contingency fee basis, meaning there is no cost to investors unless a successful recovery is made.

**5. Attention Long-Term Shareholders of Cytokinetics, Inc.**
- Source: GlobeNewswire | 20251222T140831 | Bearish | Relevance: 100%
- Grabar Law Office is investigating claims on behalf of long-term shareholders of Cytokinetics, Inc. (NASDAQ: CYTK), Holley Inc. (NYSE: HLLY), Molina Healthcare, Inc. (NYSE: MOH), and WEBTOON Entertainment, Inc. (NASDAQ: WBTN). The investigations concern alleged breaches of fiduciary duties by company officers and directors, stemming from issues like misleading statements, delayed disclosures, and the survival of securities fraud class action complaints. Shareholders with holdings prior to specified dates are encouraged to contact the law office to potentially seek corporate reforms and other remedies.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.44M) |
| Sells | 1 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.1%)
- Capital World Invest: 9.5% (-2.0%)
- Blackrock Inc.: 8.4% (-3.9%)
- Price (T.Rowe) Assoc: 6.5% (+58.8%)
- AQR Capital Manageme: 5.4% (+217.0%)

### Key Risks

1. Elevated short interest (11.4%): bears positioning against stock.
2. Long-term trend broken: trading 28.2% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.53 signals overvaluation risk, limited margin of safety. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.9B |
| Beta | 0.52 |
| 52W Range | $133.40 - $359.97 |
| Short Interest | 11.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.53 |
| Forward P/E | 10.8 |
| Current P/E | 11.8 |
| YoY Growth | 9.4% |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 8.8% to 3.5% (-5.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.5pp (needs >4.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.5% shows strong absolute momentum above own 20MA. Outperforming sector by 3.8pp, stock-specific strength. Below SMA200 (0.72x), long-term trend not supportive. MACD histogram positive (1.18), confirming momentum. RSI neutral at 60. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.47% (CS: 84) | Neutral |
| RSI_14 | 59.5 | Neutral |
| MACD Histogram | 1.18 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 0.718x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $163.99
- **Stop Loss:** $152.81 (6.8% risk)
- **Target:** $175.17 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 107
- **Position Value:** $17,546.93
- **Portfolio %:** 17.55%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-04 (Est: $0.64)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.89 | $1.84 | -52.7% |
| 2025Q2 | $5.53 | $5.48 | -0.9% |
| 2025Q1 | $5.96 | $6.08 | +2.0% |
| 2024Q4 | $5.88 | $5.05 | -14.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*